Expression profile of cathepsins indicates the potential of cathepsins B and D as prognostic factors in breast cancer patients

Figueroa-Magalhaes, 2014, Treatment of HER2-positive breast cancer, Breast, 23, 128, 10.1016/j.breast.2013.11.011

Herold, 2013, New targets for triple-negative breast cancer, Oncology (Williston Park), 27, 846

DeSantis, 2014, Breast cancer statistics, 2013, CA Cancer J Clin, 64, 52, 10.3322/caac.21203

Turk, 2000, Lysosomal cysteine proteases: More than scavengers, Biochim Biophys Acta, 1477, 98, 10.1016/S0167-4838(99)00263-0

López-Otín, 2002, Protease degradomics: A new challenge for proteomics, Nat Rev Mol Cell Biol, 3, 509, 10.1038/nrm858

Gocheva, 2007, Cysteine cathepsins and the cutting edge of cancer invasion, Cell Cycle, 6, 60, 10.4161/cc.6.1.3669

Chen, 1997, Cloning, isolation, and characterization of mammalian legumain, an asparaginyl endopeptidase, J Biol Chem, 272, 8090, 10.1074/jbc.272.12.8090

Chen, 1998, Identification of the active site of legumain links it to caspases, clostripain and gingipains in a new clan of cysteine endopeptidases, FEBS Lett, 441, 361, 10.1016/S0014-5793(98)01574-9

Im, 2007, The role of cathepsins in ocular physiology and pathology, Exp Eye Res, 84, 383, 10.1016/j.exer.2006.05.017

Tan, 2013, Cathepsins mediate tumor metastasis, World J Biol Chem, 4, 91, 10.4331/wjbc.v4.i4.91

Mohamed, 2006, Cysteine cathepsins: Multifunctional enzymes in cancer, Nat Rev Cancer, 6, 764, 10.1038/nrc1949

Jedeszko, 2004, Cysteine cathepsins in human cancer, Biol Chem, 385, 1017, 10.1515/BC.2004.132

Krepela, 2001, Cysteine proteinases in tumor cell growth and apoptosis, Neoplasma, 48, 332

Joyce, 2004, Multiple roles for cysteine cathepsins in cancer, Cell Cycle, 3, 1516, 10.4161/cc.3.12.1289

Gondi, 2013, Cathepsin B as a cancer target, Expert Opin Ther Targets, 17, 281, 10.1517/14728222.2013.740461

Frlan, 2006, Inhibitors of cathepsin B, Curr Med Chem, 13, 2309, 10.2174/092986706777935122

Masson, 2010, Pathophysiological functions of cathepsin D: Targeting its catalytic activity versus its protein binding activity?, Biochimie, 92, 1635, 10.1016/j.biochi.2010.05.009

Benes, 2008, Cathepsin D-many functions of one aspartic protease, Crit Rev Oncol Hematol, 68, 12, 10.1016/j.critrevonc.2008.02.008

Clezardin, 2011, Therapeutic targets for bone metastases in breast cancer, Breast Cancer Res, 13, 207, 10.1186/bcr2835

Huang, 2013, A prognostic model for triple-negative breast cancer patients based on node status, cathepsin-D and Ki-67 index, PLoS One, 8, e83081, 10.1371/journal.pone.0083081

Dian, 2014, Significance of the tumor protease cathepsin D for the biology of breast cancer, Histol Histopathol, 29, 433

Kawakubo, 2014, Repression of cathepsin E expression increases the risk of mammary carcinogenesis and links to poor prognosis in breast cancer, Carcinogenesis, 35, 714, 10.1093/carcin/bgt373

Bengsch, 2014, Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression, Oncogene, 33, 4474, 10.1038/onc.2013.395

Esteva, 2004, Prognostic molecular markers in early breast cancer, Breast Cancer Res, 6, 109, 10.1186/bcr777

Rochefort, 2000, Cathepsin D in breast cancer: Mechanisms and clinical applications, a 1999 overview, Clin Chim Acta, 291, 157, 10.1016/S0009-8981(99)00226-0

Tomoo, 2010, Development of cathepsin inhibitors and structure-based design of cathepsin B-specific inhibitor, Curr Top Med Chem, 10, 696, 10.2174/156802610791113441

Turk, 2012, Cysteine cathepsins: From structure, function and regulation to new frontiers, Biochim Biophys Acta, 1824, 68, 10.1016/j.bbapap.2011.10.002

Hashida, 1982, Inhibitions of cathepsin B and cathepsin L by E-64 in vivo. II. Incorporation of [3H] E-64 into rat liver lysosomes in vivo, J Biochem, 91, 1373, 10.1093/oxfordjournals.jbchem.a133825

Hara, 1988, Effect of proteinase inhibitors on intracellular processing of cathepsin B, H and L in rat macrophages, FEBS Lett, 231, 229, 10.1016/0014-5793(88)80737-3

Tsukuba, 2000, New functional aspects of cathepsin D and cathepsin E, Mol Cells, 10, 601, 10.1007/s100590000019

Garcia, 1996, Biological and clinical significance of cathepsin D in breast cancer metastasis, Stem Cells, 14, 642, 10.1002/stem.140642

Vetvicka, 2012, Procathepsin D as a tumor marker, anti-cancer drug or screening agent, Anticancer Agents Med Chem, 12, 172, 10.2174/187152012799014904

Nicotra, 2010, The dilemma: Does tissue expression of cathepsin D reflect tumor malignancy?, The question: Does the assay truly mirror cathepsin D mis-function in the tumor? Cancer Biomark, 7, 47

Markićević, 2013, Cathepsin D as an indicator of clinical outcome in early breast carcinoma during the first 3 years of follow-up, Biomark Med, 7, 747, 10.2217/bmm.13.62

Zhong, 2013, Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review), Int J Oncol, 42, 373, 10.3892/ijo.2012.1754

Nouh, 2011, A potential prognostic marker for inflammatory breast cancer, J Transl Med, 9, 1, 10.1186/1479-5876-9-1

Deaton, 2005, Design of cathepsin K inhibitors for osteoporosis, Curr Top Med Chem, 5, 1639, 10.2174/156802605775009676

Hoegl, 1999, Inhibitors of aspartic proteases in human diseases: Molecular modeling comes of age, Pharmazie, 54, 319

Withana, 2012, Cathepsin B inhibition limits bone metastasis in breast cancer, Cancer Res, 72, 1199, 10.1158/0008-5472.CAN-11-2759

Frizler, 2010, Development of nitrile-based peptidic inhibitors of cysteine cathepsins, Curr Top Med Chem, 10, 294, 10.2174/156802610790725452